Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SOL-006
- Development stage
- Preclinical
- Lead developer
- Soley Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SOL-006 is an orally bioavailable small molecule therapeutic currently in preclinical development by Soley Therapeutics for the treatment of various cancers. Developed using the company's proprietary AI-driven discovery platform, the compound is designed to target specific oncogenic drivers that have historically been difficult to address with conventional drug discovery methods. As of 2024, the specific molecular target of SOL-006 remains undisclosed by the sponsor, though the program is part of a broader effort to modulate oncogenic pathways and protein-RNA interactions that drive tumor progression and resistance.
Beyond the preview
Go deeper on SOL-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SOL-006.